Venous Thromboembolism

Venous Thromboembolism - most related articles:

- Risk of blood clots from oral contraceptive pill - 12.7
- Anemia drugs for cancer patients raises blood clots risk - 8.6
- Crestor reduced blood clots in the veins - 8.4
- Migraine linked to blood clots in veins, venous thrombosis - 8.1
- Anticoagulant Dabigatran linked to heart attack or MI - 6.8
- No increased risk of heart attacks in users of HRT - 4.3
- Oral HRT doubles risk of blood clots - 4.3
- CCSVI role in multiple sclerosis seems to be controversial - 4.1
- Ortho Evra contraceptive transdermal birth control patch label update - 3.7

Venous Thromboembolism articles

Anticoagulant Dabigatran linked to heart attack or MI
The anticoagulant dabigatran is associated with an increased risk of myocardial infarction (heart attack) or acute coronary syndrome in a broad spectrum of patients when tested against some other medicines.

Risk of blood clots from oral contraceptive pill
Researchers revealed that the combined oral contraceptive containing drospirenone carries a higher risk of venous thromboembolism than do formulations containing levonorgestrel.

Crestor reduced blood clots in the veins
A new analysis from the JUPITER study shows that CRESTOR (rosuvastatin calcium) 20mg significantly cut the risk of venous thromboembolism (VTE) by 43% compared to placebo among men and women with low to normal cholesterol levels and elevated high-sensitivity C-reactive protein (hsCRP).

Oral HRT doubles risk of blood clots
Hormone replacement therapy (HRT) given in skin patches may cause fewer blood clots than HRT given orally, revealed by researchers in British Medical Journal, UK. Women who take the oral form of HRT more than double their risk of developing a blood clot.

Anemia drugs for cancer patients raises blood clots risk
Treating anemia with a class of drugs known as erythropoiesis-stimulating agents (ESAs) is associated with an increased risk of venous thromboembolism (blood clots in the deep veins of the legs or in the lungs) and death among patients with cancer, according to an article in the February 27 issue of JAMA.

Ortho Evra contraceptive transdermal birth control patch label update
The U.S. Food and Drug Administration (FDA) approved additional changes to the Ortho Evra Contraceptive Transdermal (Skin) Patch label to include the results of a new epidemiology study that found that users of the birth control patch were at higher risk of developing serious blood clots, also known as venous thromboembolism (VTE), than women using birth control pills. VTE can lead to pulmonary embolism.

6 Venous Thromboembolism articles listed above.

List health news, Health organizations, Health news world, Glossary, Best health articles, Featured     Go to top

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information, and Health News Track is hon code accredited, verify here.
About us, Site map Privacy policy, Disclaimer
© 2007, 2008, 2009, 2010, 2011 HealthNewsTrack.com
8.47